Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)

Completed · Phase 2

Conditions studied: Rheumatoid Arthritis

In brief

The purpose of this clinical study is to see if an experimental drug, called MM-093, is safe and effective in the treatment of rheumatoid arthritis. MM-093 is a genetically engineered version of a naturally occurring protein called alpha fetoprotein (AFP). Adults normally have very small amounts of AFP in their bloodstream. However, during pregnancy, AFP levels in both the mother and the fetus are much higher than normal. It has been observed that women with RA (Rheumatoid Arthritis) have fewer symptoms during pregnancy, particularly during the third trimester. At this time, the levels of AFP in the blood of the mother and fetus are the highest. This observation led researchers to begin examining AFP as a possible treatment for RA.

Key facts

Study ID

NCT00105976

Run by

Merrimack Pharmaceuticals

People needed

260

Starts

2005-02-01

Last updated by the study team

2008-07-11

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 18-80 years
• Meet ACR (American College of Rheumatology) criteria for RA
• Have active RA consisting of 6 or more swollen and 6 or more tender joints
• Have RA for at least 6 months
• Had disease onset after 16 years old
• Currently being treated with a stable, well-tolerated dose of MTX (10 to 25 mg) given once weekly for at least 6 consecutive weeks prior to the screening visit
• Currently being treated with folic acid
• Willing to remain on a constant, once-weekly dose of MTX and folic/folinic acid throughout the duration of the study.
• Understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures being performed.
• Be able and willing to comply with study visits and procedures per protocol.
• Sexually active men must agree to use a medically acceptable form of contraception during the study and continue for 4 weeks after the last dose of study drug.
• Women of childbearing potential must use a medically acceptable means of birth control during the study and for 4 weeks after the last dose
• Must be able to store study drug in a refrigerator at home

You may not qualify if…

• Use of any B-cell depleting therapy in the last 6 months
• Use of Leflunomide or Humira in the last 3 months
• Use of any investigational drug or biologic agent in the last 2 months
• Use of Remicade in the last 2 months
• Use of cyclosporine, sulphasalazine, auranofin, intramuscular gold, azathioprine, D-penicillamine or tacrolimus within the last 6 weeks
• Use of more than 10 mg/day of prednisone or equivalent in the last 4 weeks
• Use of intra-articular corticosteroid injection in the last 4 weeks
• Use of a bolus IM/IV (intramuscular/intravenous) treatment with corticosteroids (>20 mg prednisone or equivalent) in the last 4 weeks
• Use of Enbrel in the last 4 weeks
• Use of Kineret in the last 2 weeks
• Current use of more than 1 NSAID (non-steroidal anti-inflammatory drug) or dose of NSAID greater than the maximum recommended dose in the product information
• Cancer, or a history of cancer (other than successfully resected cutaneous basal and squamous cell carcinoma) within 5 years before the screening visit.
• Any condition for which participation in this study is judged by the physician to be detrimental to the patient, such as history of significant or unstable cardiac, pulmonary, gastrointestinal, neurological, or psychiatric disease, or a DMARD (Disease-Modifying Anti-Rheumatic Drug)-related severe, potentially life-threatening AE (Adverse Event).
• Significant ongoing infection requiring systemic antibiotic, antifungal, antiviral, or any anti-mycobacterial therapy.
• Autoimmune or connective tissue disorder other than rheumatoid arthritis (e.g. systemic lupus erythematosis, scleroderma or psoriatic arthritis).
• Grade 2 or above leukopenia (i.e. white blood cells < 3000/mm3 [SI units: < 3.0 x 10\^9/L]).
• Thrombocytopenia or thrombocytosis (platelets < 125,000/mm3 or ≥ 1,000,000/mm3 [SI units: < 125 x 10\^9/L or ≥ 1,000 x 10\^9/L]), respectively.
• Grade 2 or above liver function abnormality (i.e. total bilirubin > 1.5 x the upper limit of normal; or aspartate aminotransferase [AST/SGOT] or alanine aminotransferase [ALT/SGPT] > 2.5 x upper limit of normal).
• Renal disease (including serum creatinine level > 1.5 x the upper limit of normal).
• Any history of immunodeficiency syndromes or infection with human immunodeficiency virus (HIV), or a history of hepatitis C or chronic hepatitis B.
• Pregnant or breastfeeding women or women planning to become pregnant during the study or within 4 weeks after the last dose of study drug.
• Any major surgery, including joint surgery, within 3 months before screening visit.
• Scheduled elective surgery during study participation.
• Participated in any previous clinical trial using MM-093 or have any prior exposure to MM-093.
• History of severe hypersensitivity to goat, sheep or cow milk or products derived from goat, sheep or cow milk (patients who are lactose intolerant are not excluded).

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• Montgomery Rheumatology Associates — Montgomery, Alabama, United States
• Arizona Arthritis Research, PLC — Paradise Valley, Arizona, United States
• ArthroCare, Arthritis Care and Research, Inc. — Phoenix, Arizona, United States
• Radiant Research — Scottsdale, Arizona, United States
• Arthritis Medical Center of the Central Coast — Santa Maria, California, United States
• Boling Clinical Trials — Upland, California, United States
• National Jewish Medical and Research Center — Denver, Colorado, United States
• Denver Arthritis Clinic — Denver, Colorado, United States
• New England Research Associates — Bridgeport, Connecticut, United States
• Arthritis and Rheumatic Disease Specialties — Aventura, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• International Medical Research — Ormond Beach, Florida, United States
• Sarasota Arthritis Research Center — Sarasota, Florida, United States
• Center for Arthritis and Rheumatic Diseases — South Miami, Florida, United States
• Coeur d'Alene Arthritis Clinic — Coeur d'Alene, Idaho, United States
• Illinois Bone and Joint Institute — Morton Grove, Illinois, United States
• The Arthritis Center — Springfield, Illinois, United States
• Deerbrook Medical Associates — Vernon Hills, Illinois, United States
• Rheumatology Associates, PC — Indianapolis, Indiana, United States
• Wichita Clinic — Wichita, Kansas, United States
• Rx Trials, Inc. — Columbia, Maryland, United States
• Arthritis Center of Nebraska — Lincoln, Nebraska, United States
• Arthritis Center of Reno — Reno, Nevada, United States
• Arthritis, Osteoporosis & Musculoskeletal Disease Center — Concord, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.